Adjuvant treatment of node-negative breast cancer
Merkel, D.E.; Osborne, C.K.
Texas Medicine 85(1): 32-36
1989
ISSN/ISBN: 0040-4470 PMID: 2922686 Document Number: 340596
About half of all breast cancer patients do not have axillary nodal involvement at the time of diagnosis, and this fraction will become even larger as more women participate in screening mammography programs. Recently completed trails of limited surgery have changed the primary management of node-negative disease for many women. Now, early results from a number of carefully controlled clinical trails suggest ways in which the approach to adjuvant treatment of this disease can be improved.
Document emailed within 1 workday
Related Documents
Roumen, R.M. 2000: Prognostic benefits evaluated: new guidelines for systemic adjuvant therapy for axillary node-negative breast cancer vs. implementation of sentinel node biopsy procedure Nederlands Tijdschrift Voor Geneeskunde 144(21): 980-9841990: Node-negative breast cancer: identifying those who should be spared adjuvant therapy Oncology 4(12): 15-16
Sutepvarnon, A.; Warnnissorn, M.; Srimuninnimit, V. 2013: Predictive value of Ki67 for adjuvant chemotherapy in node-negative, hormone receptor-positive breast cancer Journal of the Medical Association of Thailand 96(Suppl 2): S60-S66
Mathoulin-Portier, M.P.; Meynard, P.; Charton-Bain, M.C.; Escoute, M.; Bardou, V.J.; Puig, B.; Viens, P.; Cowen, D.; Houvenaeghel, G.; Hassoun, J.; Jacquemier, J. 1999: Peritumoral vascular invasion in women with node-negative breast cancer, receiving no adjuvant therapy Anticancer Research 19(1b): 843-847
Yamamoto, N.; Tabei, T.; Inoue, K.; Takei, H.; Sato, N.; Yanagita, Y.; Fujisawa, T.; Fujii, H.; Saeki, T.; Kurosumi, M. 2010: Tolerability and safety of docetaxel plus cyclophosphamide as adjuvant chemotherapy for axillary lymph node-negative breast cancer--JECBC04 trial Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(1): 57-63
Wang, Y.; Yao, L.; Liu, Y.-q.; Xu, Y.; Ou, Y.-t.; Li, J.-f.; Wang, T.-f.; Fan, Z.-q.; Fan, T.; Lin, B.-y.; Xie, Y.-t. 2010: Different influence of Her-2 expression on the prognosis in node-positive and node-negative breast cancer Zhonghua Zhong Liu Za Zhi 32(7): 511-514
Kohlberger, P.; Gantert, M.; Volk-Orlowska, T.; Kieback, D.G.; Gitsch, G. 2001: Immunohistochemical detection of lymph node metastases in node-negative breast cancer patients Anticancer Research 21(1b): 697-699
Karalak, A.; Homcha-Em, P. 1999: Occult axillary lymph node metastases discovered by serial section in node-negative breast cancer Journal of the Medical Association of Thailand 82(10): 1017-1019
Rudan, I.; Skorić, T.; Rudan, N. 1994: Breast cancer prognosis. I. Prognostic factors in patients with node-negative (N0) breast cancer Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 48(4-5): 159-163
Tuipae, S.; Yanaranop, M.; Oniem, N. 2012: Role of adjuvant radiotherapy after radical hysterectomy in node-negative stage IB-IIA cervical cancer with intermediate risk factors Journal of the Medical Association of Thailand 95(Suppl 3): S117-S124
Saito, A.I.; Karasawa, K. 2007: Adjuvant radiotherapy for the lymph node area of breast cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 6): 479-483
Folli, S.; Falco, G.; Mingozzi, M.; Buggi, F.; Curcio, A.; Ferrari, G.; Taffurelli, M.; Regolo, L.; Nanni, O. 2016: Repeat sentinel lymph node biopsy in patients with ipsilateral recurrent breast cancer after breast-conserving therapy and negative sentinel lymph node biopsy: a prospective study Minerva Chirurgica 71(2): 73-79
Chisholm, G.D. 1989: Treatment of invasive bladder cancer (lymph node negative, metastases negative) Progress in Clinical and Biological Research 303: 559-561
Salvadori, B.; Celio, L.; Oriana, R.; Bajetta, E. 2000: Adjuvant oophorectomy versus CMF in premenopausal node-positive breast cancer: long-term results of an experience at the Milan Cancer Institute Tumori 86(3): 258-259
Dent, D.M.; Hacking, E.A.; Gudgeon, C.A. 1989: Adjuvant therapy after surgery for breast cancer--should women without axillary node involvement be candidates South African Medical Journal 75(11): 513-514
Buchholz, T.A.; Hunt, K.K.; Amosson, C.M.; Tucker, S.L.; Strom, E.A.; McNeese, M.D.; Buzdar, A.U.; Singletary, S.E.; Hortobagyi, G.N. 1999: Sequencing of chemotherapy and radiation in lymph node-negative breast cancer Cancer Journal From Scientific American 5(3): 159-164
Gasparini, G.; Bevilacqua, P.; Dal Fior, S.; Panizzoni, G.A.; Favretto, S.; Visonà, A.; Meli, S. 1990: Characterization of node-negative breast cancer by clinico-pathologic and biologic factors Anticancer Research 10(1): 205-208
Kapranos, N.; Karaiosifidi, H.; Valavanis, C.; Kouri, E.; Vasilaros, S. 1997: Prognostic significance of apoptosis related proteins Bcl-2 and Bax in node-negative breast cancer patients Anticancer Research 17(4a): 2499-2505
Collins-Hattery, A.M.; Blumberg, B.D. 1991: S phase index and ploidy prognostic markers in node negative breast cancer: information for nurses Oncology Nursing Forum 18(1): 59-62
Li, Q.; Xu, B.-h. 2013: Clinical characteristic and management of HER-2 positive node negative small tumor breast cancer (pT1abN0) Zhonghua Yi Xue Za Zhi 93(2): 81-83